Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes

Vascular Health and Risk Management

Volumn 10, Issue , 2014, Pages 465-475

  Dardano, Angela ^a   Bianchi, Cristina ^a   Del Prato, Stefano ^a   Miccoli, Roberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Diabetes mellitus; Hypoglycemia; IDegAsp; Insulin analogs; Insulin degludec insulin aspart

Indexed keywords

INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; INSULIN DEGLUDEC, INSULIN ASPART DRUG COMBINATION; LONG ACTING INSULIN;

BOLUS INJECTION; DIABETIC PATIENT; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EMERGENCY WARD; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MAINTENANCE THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PREFERENCE; POPULATION RESEARCH; REVIEW; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; TREATMENT OUTCOME;

EID: 84907310984     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S40097     Document Type: Review

References (78)

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for2011 and2030. Diabetes Res Clin Pract.2011;94(3):311-321.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care.2012;35(6):1364-1379.
3. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med.1993;329(5):304-309.
4. [No authors listed] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2diabetes (UKPDS33). UK Prospective Diabetes Study (UKPDS) Group. Lancet.1998;352(9131):837-853.
5. [No authors listed] Effect of intensive blood-glucose control with metformin on complications in overweight patients with type2diabetes (UKPDS34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854-865.
6. [No authors listed] Retinopathy and nephropathy in patients with type1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med.2000;342(6):381-389.
7. Bailey CJ, Blonde L, Del Prato S, Leiter LA, Nesto R; Global Partnership for Effective Diabetes Management. What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diab Vasc Dis Res.2009;6(4):283-287.
8. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765-1772.
9. Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation.2011;123(3):342-348.
10. Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type1diabetes. N Engl J Med.2005;353(25):2643-2653.
11. Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care.2009;32(1):187-192.
12. Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation.2009;119(2):351-357.
13. Kong AP, Yang X, Luk A, et al. Severe hypoglycemia identifies vulnerable patients with type2diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registry. Diabetes Care. 2014;37(4):1024-1031.
14. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med.2011;365(21):2002-2012.
15. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type2diabetes. Exp Clin Endocrinol Diabetes. 2003;111(7):405-414.
16. Leese GP, Wang J, Broomhall J, et al; DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type1and type2diabetes: a population-based study of health service resource use. Diabetes Care.2003;26(4):1176-1180.
17. Bulsara MK, Holman CD, Davis EA, Jones TW. The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type1 diabetes. Diabetes Care.2004;27(10):2293-2298.
18. Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90.
19. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682-689.
20. Hirsch IB, Bode B, Courreges JP, et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type1diabetes: a26-week, phase3, randomized, open-label, treat-to-target trial. Diabetes Care.2012;35(11):2174-2181.
21. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia.1999;42(10):1151-1167.
22. Hirsch IB. Insulin analogues. N Engl J Med.2005;352(2):174-183.
23. Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad Med J.2009;85(1003):257-267.
24. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type1and type2 diabetes mellitus: scientific review. JAMA.2003;289(17):2254-2264.
25. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type2diabetes. Diabetes Care.2005;28(4):950-955.
26. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract.2007;77(1):1-15.
27. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet.2008;47(1):7-20.
28. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res.2008;6(2):54-67.
29. Owens DR, Bolli GB. Beyond the era of NPH insulin-long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther.2008;10(5):333-349.
30. Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type2diabetes: improvements and limitations. Diabetes Obes Metab. 2011;13(8):677-684.
31. Tibaldi JM. Evolution of insulin development: focus on key parameters. Adv Ther.2012;29(7):590-619.
32. Kalra S, Baruah MP, Niazi AK. Degludec: a novel basal insulin. Recent Pat Endocr Metab Immune Drug Discov.2012;6(1):18-23.
33. European Medicines Agency. Tresiba (insulin degludec): EU summary of product characteristics;2013. Available from: http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/002498/WC500138940.pdf. AccessedFebruary 1, 2013.
34. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res.2012;29(8):2104-2114.
35. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type1 diabetes. Diabetes Obes Metab.2012;14(9):859-864.
36. Wang F, Surh J, Kaur M. Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review. Diabetes Metab Syndr Obes. 2012;5:191-204.
37. Goldman-Levine JD, Patel DK, Schnee DM. Insulin degludec: a novel basal insulin analogue. Ann Pharmacother.2013;47(2):269-277.
38. Keating GM. Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus. Drugs. 2013;73(6):575-593.
39. Gough SC, Harris S, Woo V, Davies M. Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes Obes Metab.2013;15(4): 301-309.
40. Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care.2011;34(3):661-665.
41. Heller S, Buse J, Fisher M, et al; BEGIN Basal-Bolus Type1Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1diabetes (BEGIN Basal-Bolus Type1): a phase3, randomised, open-label, treat-to-target non-inferiority trial. Lancet.2012;379(9825):1489-1497.
42. Mathieu C, Hollander P, Miranda-Palma B, et al; NN1250-3770 (BEGIN: Flex T1) Trial Investigators. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type1diabetes (BEGIN: Flex T1): a26-week randomized, treatto-target trial with a26-week extension. J Clin Endocrinol Metab. 2013;98(3):1154-1162.
43. Bode BW, Buse JB, Fisher M, et al; BEGIN ® Basal-Bolus Type 1 trial investigators. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1):2-year results of a randomized clinical trial. Diabet Med.2013;30(11):1293-1297.
44. Koehler G, Heller S, Korsatko S, et al. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type1diabetes: a double-blind randomised crossover study. Diabetologia.2014;57(1):40-49.
45. Korsatko S, Deller S, Mader JK, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type1diabetes mellitus. Drugs Aging.2014;31(1): 47-53.
46. Biester T, Blaesig S, Remus K, et al. Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type1 diabetes. Pediatr Diabetes. 2014;15(1):27-33.
47. Davies MJ, Gross JL, Ono Y, et al; on behalf of the BEGIN BB T1 study group. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type1diabetes: a26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. Epub 2014 Apr 7.
48. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-longacting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type2 diabetes: a16-week, randomised, open-label, phase2 trial. Lancet.2011;377(9769): 924-931.
49. Garber AJ, King AB, Del Prato S, et al; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type2diabetes (BEGIN Basal-Bolus Type2): a phase3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498-1507.
50. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stableglucose-lowering effect in type2 diabetes. Diabetes Obes Metab.2012;14(10):944-950.
51. Zinman B, Philis-Tsimikas A, Cariou B, et al; NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type2 diabetes: a1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464-2471.
52. Meneghini L, Atkin SL, Gough SC, et al; NN1250-3668 (BEGIN FLEX) Trial Investigators. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2diabetes. Diabetes Care.2013;36(4):858-864.
53. Philis-Tsimikas A, Del Prato S, Satman I, et al. Effect of insulin degludec versus sitagliptin in patients with type2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab.2013;15(8): 760-766.
54. Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type2diabetes: a26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care.2013;36(9): 2536-2542.
55. Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Insulin degludec once-daily in type2 diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther. 2013;30(6):607-622.
56. Rodbard HW, Cariou B, Zinman B, et al; BEGIN Once Long trial investigators. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a2-year randomized, treat-to-target trial. Diabet Med.2013;30(11):1298-1304.
57. Zinman B, DeVries JH, Bode B, et al; NN1250-3724 (BEGIN:EASY AM) and NN1250-3718 (BEGIN:EASY PM) Trial Investigators. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type2diabetes: results of two phase3,26 week, randomised, open-label, treat-to-target, noninferiority trials. Lancet Diabetes Endocrinol.2013;1(2):123-131.
58. Kiss I, Arold G, Roepstorff C, Bøttcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet.2014;53(2):175-183.
59. Kupčová V, Arold G, Roepstorff C, Højbjerre M, Klim S, Haahr H. Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Investig.2014;34(2):127-133.
60. Mathieu C, Rodbard HW, Cariou B, et al; on behalf of the BEGIN: VICTOZA ADD-ON (NN1250-3948) study group. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type2diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. Epub January20, 2014.
61. Rodbard HW, Cariou B, Zinman B, et al. Health status and hypoglycaemia with insulin degludec versus insulin glargine: a2-year trial in insulin-naïve patients with type2diabetes. Diabetes Obes Metab. Epub February4, 2014.
62. Hompesch M, Morrow L, Watkins E, Roepstorff C, Thomsen HF, Haahr H. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type2diabetes mellitus. Clin Ther.2014;36(4):507-515.
63. Bode BW, Chaykin LB, Sussman AM, et al. Efficacy and Safety of Insulin Degludec200 U/ML and Insulin Degludec100 U/ML in Patients with Type2Diabetes (Begin: Compare). Endocr Pract. Epub February11, 2014:1-16.
64. European Medicines Agency. Ryzodeg (insulin degludec/insulin aspart): EU summary of product characteristics;2013. Available from: http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_ Information/human/002499/WC500139011.pdf. Accessed February1, 2013.
65. Ma Z, Parkner T, Christiansen JS, Laursen T. IDegAsp: a novel soluble insulin analogs combination. Expert Opin Biol Ther.2012;12(11): 1533-1540.
66. Heller S, Kurtzhals P, Verge D, Lindholm A. Insulin aspart: promising early results borne out in clinical practice. Expert Opin Pharmacother. 2002;3(2):183-195.
67. Østerberg O, Erichsen L, Ingwersen SH, Plum A, Poulsen HE, Vicini P. Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. J Pharmacokinet Pharmacodyn.2003;30(3): 221-235.
68. Home PD. The pharmacokinetics and pharmacodynamics of rapidacting insulin analogues and their clinical consequences. Diabetes Obes Metab.2012;14(9):780-788.
69. Reynolds NA, Wagstaff AJ. Insulin aspart: a review of its use in the management of type1 or2 diabetes mellitus. Drugs.2004;64(17): 1957-1974.
70. Heller S, McCance DR, Moghissi E, Nazeri A, Kordonouri O. Diversity in diabetes: the role of insulin aspart. Diabetes Metab Res Rev. 2012;28(1):50-61.
71. Rendell M. Insulin degludec: a long-acting modern insulin analogue with a predictablepharmacokinetic/pharmacodynamic profile. Drugs Today (Barc).2013;49(6):387-397.
72. Poon K, King AB. Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs. Drug Healthc Patient Saf. 2010;2:213-223.
73. European Medicines Agency. EPAR summary for the public: Ryzodeg (insulin degludec/insulin aspart). Available from: http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_ public/human/002499/WC500139014.pdf. Accessed July 1, 2014.
74. Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type2diabetes: a randomized, controlled trial. Diabetes Care.2011;34(3):669-674.
75. Niskanen L, Leiter LA, Franek E, et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart30 in type2 diabetes: a randomised trial. Eur J Endocrinol. 2012;167(2):287-294.
76. Liebl A, Davidson J, Mersebach H, Dykiel P, Tack CJ, Heise T. A novel insulin combination of insulin degludec and insulin aspart achieves a more stableovernight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial. J Diabetes Sci Technol.2013;7(5):1328-1336.
77. Onishi Y, Ono Y, Rabøl R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type2diabetes inadequately controlled with oral drugs: a randomized, controlled phase3trial. Diabetes Obes Metab.2013;15(9):826-832.
78. Bonora E. Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives. Int J Clin Pract Suppl.2002;129:5-11.